CYP2C19 PHENOTYPE AND ADVERSE EVENTS DURING SERTRALINE TREATMENT IN CHILDREN AND ADOLESCENTS.

被引：0
|
作者：
Neely, K. [1 ]
Aka, I. [1 ]
Maxwell-Horn, A. [1 ]
Roden, D. [1 ]
Van Driest, S. [1 ]
机构：
[1] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PGRN-018
引用
收藏
页码：S17 / S17
页数：1
相关论文
共 50 条
  • [1] CYP2C19 PHENOTYPE AND ADVERSE EVENTS DURING SERTRALINE TREATMENT IN CHILDREN AND ADOLESCENTS.
    Neely, K.
    Aka, I.
    Maxwell-Horn, A.
    Roden, D.
    Van Driest, S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S56 - S56
  • [2] CYP2C19 METABOLIZER PHENOTYPE INFLUENCES SERTRALINE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS.
    Vaughn, S.
    Poweleit, E.
    Desta, Z.
    Strawn, J.
    Ramsey, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S54 - S54
  • [3] CYP2C19 METABOLIZER PHENOTYPE PREDICTS SERTRALINE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS
    Poweleit, Ethan
    Vaughn, Samuel
    Desta, Zeruesenay
    Strawn, Jeffrey
    Ramsey, Laura
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 51 : E132 - E132
  • [4] Sertraline dosing trends in children and adolescents stratified by CYP2C19 genotype
    Brown, Jacob T.
    Gregornik, David B.
    Jorgenson, Alissa
    Watson, Dave
    Roiko, Samuel A.
    Bishop, Jeffrey R.
    [J]. PHARMACOGENOMICS, 2022, 23 (04) : 247 - 253
  • [5] PHARMACOGENETIC INFLUENCE OF CYP2C19 VARIATION ON ESCITALOPRAM PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS.
    Poweleit, E.
    Vaughn, S.
    Desta, Z.
    Strawn, J.
    Ramsey, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S41 - S41
  • [6] CYP2C19 Metabolizer Status Predicts Sertraline and Escitalopram Pharmacokinetics in Children and Adolescents
    Poweleit, Ethan
    Vaughn, Samuel
    Desta, Zeruesenay
    Ramsey, Laura
    Strawn, Jeffrey
    [J]. NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 154 - 154
  • [7] CYP2D6 POLYMORPHISMS AND ADVERSE EVENTS TO RISPERIDONE IN CHILDREN AND ADOLESCENTS.
    Neely, K. M.
    Oshikoya, K. A.
    Carroll, R.
    Aka, I.
    Maxwell-Horn, A.
    Roden, D. M.
    Van Driest, S. L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S22 - S23
  • [8] CYP2D6 POLYMORPHISMS AND ADVERSE EVENTS TO RISPERIDONE IN CHILDREN AND ADOLESCENTS.
    Neely, K. M.
    Oshikoya, K. A.
    Carroll, R.
    Aka, I.
    Maxwell-Horn, A.
    Roden, D. M.
    Van Driest, S. L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S107 - S108
  • [9] CYP2C19 PHENOTYPE, RESPONSE RATE, AND ADVERSE EVENTS OF (ES)CITALOPRAM IN A PEDIATRIC COHORT.
    Van Driest, S.
    Aka, I.
    Neely, K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S56 - S56
  • [10] CYP2C19 PHENOTYPE, RESPONSE RATE, AND ADVERSE EVENTS OF (ES)CITALOPRAM IN A PEDIATRIC COHORT.
    Van Driest, S.
    Aka, I.
    Neely, K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S17 - S17
12345